Bibliometric analysis of laryngeal cancer treatment literature (2003–2023) by Yan Zhao, Jiancheng Xue

“…Conclusions: There is an urgent need to enhance global scholarly communication as the pursuit of effective laryngeal cancer treatment progresses. Focused research on targeting indicators for this type of cancer remains vital. …”
Get full text

The initial results of using brolucizumab (Beovu®), an angiogenesis inhibitor, for choroidal neovascularization in patients with age-related macular degeneration by N.S. Zhayvoronok, O.V. Kolenko, L.P. Danilova, E.L. Sorokin

“…</p> <p> <b>Conclusions</b>: after each injection of brolucizumab, there was a statistically significant progressive reduction in macular parameters, CRT and MV, coupled with an increase in mean BCVA values. …”
Get full text

Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack by Bingxun Wang, Yongqing Liu, Wenya Han, Bing Li, Pang Jie, Wenwen Yang, Zengcai Ma, Zesheng Xu

“…Conclusions: Colchicine adjuvant therapy improves the efficacy of CHD patients with acute gout attacks, helps improve cardiac function and vascular endothelial function, reduces serum levels of NALP3, sICAM-1, MMP-9, and MMP-13, enhances patient immunity, and controls disease progression.…”
Get full text

Phenotypes of primary sclerosing cholangitis in children by M.B. Dyba, V.S. Berezenko

“…Although immunosuppressive therapy is effective in controlling autoimmune inflammation, it does not inhibit the progression of fibrotic changes around the bile ducts, which, unfortunately, leads to the formation of biliary cirrhosis of the liver. …”
Get full text

The fibrosis-4 index and its association with carotid atherosclerosis in type 2 diabetes: a cross-sectional study in China by Ying Miao, Yu Wang, Qin Wan, Nanwei Tong

“…Following adjustments for various factors, the prevalence of CA exhibited a progressive increase in the Fib-4 < 1.3, 1.3 ≤ Fib-4 < 2.67, and Fib-4 ≥ 2.67 groups, with statistically significant differences (P < 0.05). …”
Get full text

Level-8 Ph.D. Programs In Medical Sciences: High Time For The Higher Education Commission (HEC) Of Pakistan To Establish A Medical Wing by Wafa Omer

“…How can a clinician not be a researcher considering the pace at which the global medical community and advancements in medical science are progressing and how can a practising physician bid farewell to clinical practice just because he is labelled to be a researcher only? …”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…Patients received D (1500 mg IV) + TM (75 mg IV) on Day 1 q4 weeks for 4 cycles followed by D q4 weeks until disease progression. This trial is registered with ClinicalTrials.gov, NCT02879162. …”
Get full text

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis by Roberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, Alessandra Longobardi, Giuliana Pavone, Pierluigi De Santis, Roberta Caputo, Carmine De Angelis, Lucia Del Mastro, Fabio Puglisi, Mario Giuliano, Grazia Arpino, Martina Pagliuca, Michelino De Laurentiis

“…We included studies comparing CDK4/6i (palbociclib, ribociclib, abemaciclib, dalpiciclib) + ET versus placebo + ET. Progression-free survival (PFS) and overall survival (OS), hazard ratios (HR), and 95 % confidence intervals (CI) were extracted for the two subgroups of interest. …”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review... by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

“…This meta-analysis aimed to assess the efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor (CP) in the treatment of patients with advanced NSCLC.MethodsA systemic search was conducted in four databases (PubMed, Cochrane library, Embase, and Web of Science) from their establishment until January 17, 2024, for randomized controlled trials that investigated the use of the first-line PD-1/PD-L1 inhibitor plus CTLA-4 inhibitor in patients with advanced NSCLC. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were subjected to meta-analyses.ResultsTotally 7 eligible randomized controlled trials including 4682 people were included. …”
Get full text

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas by Gohar S. Manzar, Chelsea C. Pinnix, Stephanie O. Dudzinski, Kathryn E. Marqueen, Elaine E. Cha, Lewis F. Nasr, Alison K. Yoder, Michael K. Rooney, Paolo Strati, Sairah Ahmed, Chijioke Nze, Ranjit Nair, Luis E. Fayad, Michael Wang, Loretta J. Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Jillian R. Gunther, Bouthaina S. Dabaja, Susan Y. Wu, Penny Q. Fang

“…Median overall survival (OS) was 22.1 months (6.6-not reached) and the median progression-free survival (PFS) was 7.4 months (5.5-30). …”
Get full text

The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles by Michiel T.H.M. Henkens, Anne‐Mar vanOmmen, Sharon Remmelzwaal, Gideon B. Valstar, Ping Wang, Job A.J. Verdonschot, Mark R. Hazebroek, Leonard Hofstra, Vanessa P.M. vanEmpel, Joline W.J. Beulens, Hester M. denRuijter, Stephane R.B. Heymans

“…Recognizing early‐HFpEF phenogroups is essential to better understand progression towards overt HFpEF and pave the way for early intervention and treatment. …”
Get full text

Automated Synthesis and Initial Evaluation of (4′-Amino-5′,8′-difluoro-1′H-spiro[piperidine-4,2′-quinazolin]-1-yl)(4-[18F]fluorophenyl)methanone for PET/MR Imaging of Inducible Nit... by Skye Hsin-Hsien Yeh, Wen-Sheng Huang, Chuang-Hsin Chiu, Chuan-Lin Chen, Hui-Ting Chen, Dae Yoon Chi, Zhengxing Ge, Tsung-Hsun Yu, Pao-Yeh Wang, Yu-Yeh Kuo, Chun-Tse Hung, Geng-Ying Li, Chi-Wei Chang

“…In vitro, [18F]FBAT rapidly and progressively accumulated in murine microglial BV2 cells exposed to LPS; however, [18F]FBAT accumulation was inhibited by aminoguanidine, a selective iNOS inhibitor. …”
Get full text

Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins by Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Ailing Huang, Lisa K. Duong, Qi Wang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Bo Wei, Wai-Kin Chan, Kevin Lin, Jie Zhang, Efrosini Tsouko, Shonik Ganjoo, Hampartsoum B. Barsoumian, Thomas S. Riad, Yun Hu, Carola Leuschner, Nahum Puebla-Osorio, Jing Wang, Jian Hu, Michael A. Davies, Vinay K. Puduvalli, Cyrielle Billon, Thomas P. Burris, Philip L. Lorenzi, Boyi Gan, James W. Welsh

“…Clinical trial data revealed that higher FABP7 expression correlates with poorer overall survival and progression-free survival in patients undergoing immunotherapy. …”
Get full text

Non-coding RNAs secreted by renal cancer include piR_004153 that promotes migration of mesenchymal stromal cells by Joanna Bogusławska, Małgorzata Grzanka, Piotr Popławski, Weronika Zarychta-Wiśniewska, Anna Burdzinska, Karolina Hanusek, Helena Kossowska, Roksana Iwanicka-Nowicka, Alex Białas, Beata Rybicka, Anna Adamiok-Ostrowska, Joanna Życka-Krzesińska, Marta Koblowska, Leszek Pączek, Agnieszka Piekiełko-Witkowska

“…Mesenchymal stromal cells (MSCs) are components of tumor microenvironment (TME) that influence RCC progression. The impact of RCC-secreted small non-coding RNAs (sncRNAs) on TME is largely underexplored. …”
Get full text

Gut bacteria Prevotellaceae related lithocholic acid metabolism promotes colonic inflammation by Liping Chen, Zhenghao Ye, Junhua Li, Lijia Wang, Yu Chen, Meiping Yu, Jian Han, Jiangeng Huang, Dongyan Li, Yongling Lv, Kai Xiong, De’an Tian, Jiazhi Liao, Ursula Seidler, Fang Xiao

“…Subsequent experiments confirmed that LCA supplementation effectively mitigated the inhibitory effects of gut microbiota on colitis progression in mice, primarily through the activation of the sphingosine-1-phosphate receptor 2 (S1PR2)/NF-κB p65 signaling pathway. …”
Get full text

Inter-pregnancy interval and uterine rupture during a trial of labour after one previous caesarean delivery and no previous vaginal births: a retrospective population-based cohort... by Pejman Adily, Travis Bettison, Mark Lauer, Rajit Narayan, Adam Mackie, Hala Phipps, Vincenzo Berghella, Marjan M. Haghighi, Katelyn Perren, George Johnson, Bradley de Vries

“…Interpretation: The risk of uterine rupture progressively decreases as IPI increases until about 21 months and then stabilises. …”
Get full text

Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological association by V. T. Ivashkin, I. V. Mayev, I. . A.s. Trukhmanov, Ye. K. Baranskaya, O. B. Dronova, O. V. Zayratyants, R. G. Sayfutdinov, A. A. Sheptulin, T. L. Lapina, S. S. Pirogov, Yu. A. Kucheryavy, O. A. Storonova, D. N. Andreyev

“…The goal of treatment is symptom relief, at erosive esophagitis - healing of erosions and complication prevention, at Barret's esophagus - prophylaxis of disease progression and dysplasia and adenocarcinoma development. …”
Get full text

Impact of Ketogenic and Mediterranean Diets on Gut Microbiota Profile and Clinical Outcomes in Drug-Naïve Patients with Diabesity: A 12-Month Pilot Study by Vanessa Palmas, Andrea Deledda, Vitor Heidrich, Giuseppina Sanna, Giulia Cambarau, Michele Fosci, Lorenzo Puglia, Enrico Antonio Cappai, Alessio Lai, Andrea Loviselli, Aldo Manzin, Fernanda Velluzzi

“…A substantial positive modulatory effect was observed especially up to the sixth month of the NI in KETO due to the progressive increase in bacterial markers of human health. …”
Get full text

SLC31A1 promotes chemoresistance through inducing CPT1A-mediated fatty acid oxidation in ER-positive breast cancer by Xudong Li, Jingjing Ge, Mengdi Wan, Tongtong Feng, Xiaoqian Li, Haibo Zhang, Zhangyan Wang, Yongsheng Gao, Meiting Chen, Fei Pan

“…RNA-Seq analysis indicated that FAO might be implicated in SLC31A1-mediated breast cancer progression. CPT1A was also overexpressed in TAM-resistant breast cancer cells, accompanied by enhanced FAO rates and ATP levels. …”
Get full text

Evaluation of Learners’ Satisfaction with Open Flexible and Distance Learning Services at the University of Lagos Distance Learning Institute by Adenike Oladipo, Esther O. Oladele, Oladipupo Ajeyalemi, Folashade Afolabi, Peter O. Olayiwola, Johnson A. Adewara, Andrew Akala, Uchenna Udeani

“…Les résultats de cette étude ont révélé que la DLI a moins de marge de progression pour satisfaire les apprenants aux stades de la préinscription, du processus et du produit, avec des réponses moyennes de 7,27, 5,63 et 6,87 respectivement. …”
Get full text